Vanda Pharmaceuticals, Inc. (VNDA) Posts Q2 Loss of 28c/Share
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.33 -1.84%
Revenue Growth %: +24.1%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q2 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $8.38 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- BMO Capital Starts Carter's (CRI) at Outperform
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
